StemCell Therapy

DUBLIN--(BUSINESS WIRE)--The "Leber's Hereditary Optic Neuropathy (Leber optic atrophy) - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 2, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Phase III and Phase I stages comprises 1 and 1 molecules, respectively.

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

Reasons to buy

Key Topics Covered:

Introduction

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Overview

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Therapeutics Development

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Therapeutics Assessment

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Companies Involved in Therapeutics Development

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drug Profiles

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Dormant Projects

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Product Development Milestones

Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hp1wmj

Originally posted here:

Leber's Hereditary Optic Neuropathy, 2019 - Pipeline Review, H2 - ResearchAndMarkets.com - Business Wire

This entry was posted on January 3, 2020 at 8:44 am and is filed under Neuropathy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |